Ivf

Miami, FL

13 Ivf Trials near Miami, FL

Power is an online platform that helps thousands of Ivf patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication
The goal of this clinical trial is to evaluate the safety and efficacy of using Fertilo for In vitro maturation (IVM) in participants 18-35 years of age. The main question it aims to answer is whether the use of Fertilo is superior to using Medicult IVM for In vitro maturation. Researchers will compare the number of ongoing pregnancies at 12 weeks gestation for participants in each arm. * Arm 1 participants will have all cumulus oocyte complexes (COCs), or eggs surrounded by helper cells, cultured in Fertilo for 30 hours. * Arm 2 participants will have all cumulus oocyte complexes (COCs), or eggs surrounded by helper cells, cultured in Medicult IVM for 30 hours.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 35
Sex:Female

500 Participants Needed

ROSI for Male Infertility

Winston-Salem, North Carolina
This trial is testing a procedure that uses immature sperm cells to help men who can't produce mature sperm have biological children. The process involves selecting these cells and injecting them into an egg, with extra steps to ensure the egg is ready to develop. This technique has been explored as an alternative for men who cannot produce mature sperm.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Sex:Male

50 Participants Needed

To determine if a nonsteroidal anti-inflammatory drug (NSAID), Ketorolac (Toradol), can improve pain control and decrease narcotic use after undergoing egg retrieval.

Trial Details

Trial Status:Recruiting
Age:18 - 45
Sex:Female

400 Participants Needed

Currently, patients presenting to the Fertility and Reproductive Medicine Center meet with an English-speaking provider and communicate through an interpreter, as none of the physicians speak Spanish. However, this study PI is a native Spanish speaker and certified bilingual clinician. Thus, this study is looking to evaluate whether or not the use of an interpreter delays completion of testing and initiation of fertility treatment. The medically indicated testing, procedures, and course of treatment will not be altered as a result of participation in the study. Participants will be asked to complete a survey in their preferred language to gauge satisfaction and communication efficacy. This proposed study is significant as it seeks to address a critical gap in the understanding of how language concordance between healthcare providers and patients influences treatment outcomes in fertility care. With Spanish being the most commonly spoken non-English language in the U.S., evaluating the impact of Spanish language skills in medical care is both timely and essential. This research will shed light on whether Spanish-speaking patients experience better treatment progression and outcomes when cared for by language-concordant providers versus when interpreters are used in fertility care. This prospective study will be conducted at Washington University's Fertility and Reproductive Medicine Center over a 12-month period. The investigators aim to enroll a total of 70 Spanish-speaking patients, based on previous patient trends at the Center 35 will be randomized to the intervention group (being evaluated and treated by a Spanish-speaking provider), and 35 will be randomized to standard of care (communicating with an English-speaking provider through an interpreter).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Sex:Female

70 Participants Needed

This study aims to assess the effect of age of the male partner and the reproductive ability of sperm prepared via sperm selection devices (Zymot) compared to routine embryologist selected sperm after density gradient centrifugation (DGC) preparation for intracytoplasmic sperm injection (ICSI) in patients undergoing in vitro fertilization treatment (IVF) of their infertility.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 41
Sex:Female

100 Participants Needed

The use of machine learning techniques using an artificial intelligence tool is proposed to analyze clinical data to predict best possible IVF/ART outcomes. This tool has been utilized to accurately predict embryo quality here at Cornell. Utilizing this tool to assess objective clinical findings and predict outcomes of assisted reproductive techniques is sought, with the ultimate goal of an automated tool to reduce implicit physician bias. Within this goal, using this tool to objectively and accurately assess baseline ovarian reserve at the start of an ART cycle is proposed, using 3D sonography to image the ovary and artificial intelligence tool to objectively identify baseline antral follicle counts.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

4000 Participants Needed

This prospective double-blinded randomized placebo control study aims to determine if In Vitro Fertilization (IVF) outcomes are improved by ovarian platelet-rich plasma injections (oPRP) for women diagnosed with diminished ovarian reserve (DOR). Women with DOR notoriously have the lowest chance of pregnancy and live birth compared to age-matched peers with a normal or robust ovarian reserve.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:35 - 42
Sex:Female

230 Participants Needed

This trial is testing a method to choose sperm that will result in either a boy or a girl before fertilization. It targets couples undergoing infertility treatment. The process involves sorting sperm by density to identify male or female sperm, then using them for fertilization procedures like IVF or intrauterine insemination.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

2000 Participants Needed

In this proposed research study, the investigators plan to assess the efficacy of gametes' (egg and sperm) treatment on fertilization as well as pre- and post-implantation embryo development.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:21 - 89

1200 Participants Needed

Ovarian reserve defines the quantity and quality of the ovarian primordial follicular pool. Diminished ovarian reserve (DOR) indicates a reduction in the quantity of ovarian follicular pool to less than expected for age. It is an important cause of infertility in many couples. To date, there is no clear consensus in the literature on the definition of diminished ovarian reserve, and it is unclear whether low oocyte yield results from an abnormal atresia rate of the follicle pool, or from a lower follicle pool at birth or whether it can just occur as a normal variation in the population. The ovarian response to controlled ovarian stimulation with gonadotropins (for example, for in vitro fertilization) is largely determined by the ovarian reserve, and there are numerous different ovarian stimulation protocols that are employed to try and increase the oocyte yield of a particular cycle. There is no consensus on which, if any, of these protocols are superior and preferred for patient with DOR. Luteal gonadotropin stimulation is a protocol of controlled ovarian stimulation (COS) for use in assisted reproductive technologies (ART) that has emerged over the past decade as an acceptable alternative to the classic follicular gonadotropin stimulation. The luteal estradiol patch protocol was introduced in 2005 in patients with poor response to controlled ovarian stimulation (COS) and to address the phenomenon of early follicle recruitment in patients with diminished ovarian reserve (DOR). Luteal gonadotropin stimulation can potentially achieve the same effect by initiating follicular recruitment for IVF prior to the body's own premature recruitment. Our hypothesis is that the luteal stimulation protocol and estradiol priming protocol are equivalent with regard to the outcome of number of mature oocytes retrieved. Patients who will be undergoing controlled ovarian stimulation and who have a diagnosis of diminished ovarian reserve will be considered for this trial, and enrolled if meeting all inclusion and no exclusion criteria.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:20 - 45
Sex:Female

142 Participants Needed

The objective of this study is to determine if ubiquinol will result in improved reproductive outcomes in older women at a reduced oral dose compared to current standard treatment with ubiquinone.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:37 - 43
Sex:Female

90 Participants Needed

The goal of this clinical trial is to evaluate the safety and effectiveness of a personalized ovarian stimulation regimen in women aged 18 to 40 undergoing in vitro fertilization (IVF). The main question it aims to answer is: - Does personalizing the starting doses of follitropin delta (REKOVELLE) and HP-hMG (MENOPUR) based on both age and body lead to similar results as anti-Müllerian hormone (AMH) and weight based dosing ? Researchers will compare the new dosing regimen to the MARCS study results to see if this new approach leads to similar outcomes Participants will: * Receive ovarian stimulation using a personalized dose of REKOVELLE aND MENOPUR based on age and weight * Be monitored through ultrasound imaging and blood tests to measure estradiol (E2) levels * Undergo standard IVF procedures including egg retrieval and embryo assessment
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 2
Age:18 - 40
Sex:Female

200 Participants Needed

CCRM Fertility, a global pioneer in fertility treatment, research and science, is seeking participants for a new study on in vitro maturation (IVM). IVM requires less hormones to stimulate the ovaries than IVF, making it more affordable than IVF with fewer side effects. Participants that qualify for the study will receive a free cycle of IVM treatment at CCRM Fertility and including a new patient consultation, fertility testing, preimplantation genetic testing for aneuploidies (PGT-A), anesthesia and some medication
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:< 38
Sex:Female

50 Participants Needed

Why Other Patients Applied

"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

ID
Pancreatic Cancer PatientAge: 40

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38

"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

ZS
Depression PatientAge: 51

"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

AG
Paralysis PatientAge: 50

"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

HZ
Arthritis PatientAge: 78

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials

Frequently Asked Questions

How much do Ivf clinical trials in Miami, FL pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Ivf clinical trials in Miami, FL work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Ivf trials in Miami, FL 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Miami, FL for Ivf is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Miami, FL several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Ivf medical study in Miami, FL?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Ivf clinical trials in Miami, FL?

Most recently, we added Follitropin Delta + HP-hMG for In Vitro Fertilization, Fertilo for In Vitro Maturation and Sperm Selection Methods for Infertility to the Power online platform.

Which type of IVF is best?

There isn’t one “best” IVF for everyone—what works best depends on your situation. Conventional high-dose IVF (or IVF + ICSI for severe male-factor infertility) is often chosen when you need the highest number of embryos quickly, mild/mini-stim or natural-cycle IVF can suit women who want lower drug exposure or have low ovarian reserve, and donor-egg IVF gives the highest success when egg quality is the main problem. Talk with a reproductive endocrinologist about your age, egg and sperm tests, medical risks, budget, and how many children you hope for; those factors together point to the right IVF strategy for you.

What are the unintended consequences of IVF?

Think of IVF risks in three stages. 1) During treatment: strong fertility drugs can occasionally cause ovarian-hyperstimulation (pain, fluid build-up; severe forms in <1 % of cycles) and procedures carry small risks of bleeding or infection. 2) During pregnancy: because more than one embryo may take, twins or triplets are more common, raising chances of miscarriage, high blood pressure, C-section, or premature birth; single-embryo transfer and careful monitoring now cut this risk sharply. 3) For the child and family: babies from IVF are mostly healthy, but studies show a small increase in low birth-weight and certain birth defects (roughly 1–2 extra cases per 100 births), and families must also weigh the emotional stress and financial cost of repeated cycles. Discussing embryo number, drug dosing, and support resources with your fertility team is the main way to minimise these unintended consequences.

Why are IVF meds so expensive?

IVF drug prices are high because several costs stack on top of one another: they are expensive biologic proteins to manufacture, sold to a relatively small group of patients, protected by patents with few biosimilar competitors, and dispensed through specialty pharmacies with little insurance price pressure—together this keeps per-cycle medication bills in the roughly $3,000-$5,000 range in the U.S. Ask your clinic about lower-cost urinary or biosimilar gonadotropins, manufacturer “compassionate-care” discounts, and price quotes from multiple specialty pharmacies; these steps can shave hundreds to thousands of dollars from that total.

What are the odds of getting a successful IVF?

Success in IVF is usually measured by a live-birth: in the most recent CDC data a woman under 35 averages about a 45 % chance per cycle, 35-37 yrs about 35 %, 38-40 yrs about 25 %, and over 40 yrs 5-15 %; when you add two more cycles the cumulative chance rises to roughly 65-70 %, 60 %, 50 %, and 20-30 % respectively. Age is the single biggest predictor, but clinic expertise, cause of infertility, embryo testing, and lifestyle (weight, smoking) can raise or lower these odds, so ask your clinic for their age-specific live-birth rates when deciding how many cycles to attempt.

Did Courteney Cox do IVF?

Yes. Courteney Cox has said she went through several rounds of in-vitro fertilisation after suffering repeated miscarriages and, once doctors treated an underlying blood-clotting/antibody problem with blood thinners, one IVF cycle led to the successful pregnancy that produced her daughter Coco in 2004. Claims that an MTHFR gene mutation was the specific cause come from secondary websites rather than Cox’s own statements or medical reports and are not supported by current medical evidence.

Why is IVF controversial?

IVF sparks debate for three main reasons: it routinely creates extra embryos whose freezing, testing or disposal some religions and bioethicists view as ending a life; the hormone treatments and transfer of multiple embryos can put mothers and babies at higher medical risk; and its high price, use by single or same-sex parents, and patchwork laws force society to ask who should access or regulate it. In short, IVF sits at the intersection of embryo ethics, patient safety and shifting social norms, so people’s views vary with the weight they give each of those concerns.

Are IVF babies more likely to have ADHD?

Large national studies that account for prematurity, twins and parental health find no meaningful increase in ADHD among children conceived with IVF; any small uptick seen in a few analyses (≈10 % relative, <1 per 1 000 absolute) disappears when those other factors are included. In short, current evidence says the lab process of IVF is not a direct cause of ADHD—focusing on a healthy single-baby pregnancy and routine pediatric follow-up remains the best way to support your child.

Is IVF hard on the body?

IVF does put extra demands on your body—most people feel bloating, mood swings and a day or two of pelvic soreness, while serious problems like severe ovarian-hyperstimulation happen in fewer than 2 % of cycles and are closely monitored. With today’s gentler drug protocols, good pain control and prompt follow-up, the physical effects are usually short-lived, so the bigger challenge for many couples is managing stress and expectations rather than long-term harm. Most patients are back to normal activities within a few days; call your clinic right away if you have sudden severe pain, rapid weight gain or trouble breathing.

How to get more mature eggs IVF?

A “mature” egg is one that has reached the M-II stage so it can be fertilised—your goal is to raise both the number and the percentage of these eggs. Ask your doctor about protocol tweaks that research shows can help, such as adding a little LH during stimulation, using a “dual-trigger” (GnRH-agonist plus low-dose hCG) 36 hours before retrieval, or starting supplements like DHEA or CoQ10 6–8 weeks beforehand if you have low ovarian reserve. At home, keep a healthy BMI, avoid tobacco/alcohol, and follow a Mediterranean-style diet and moderate exercise; these steps improve blood flow and hormone balance but work best when combined with the right medication plan.

Who is a bad candidate for IVF?

IVF is usually discouraged when (1) the woman has almost no usable eggs and will not consider donor eggs, (2) serious medical conditions or extreme obesity make pregnancy hazardous, or (3) the uterus is so damaged or absent that it cannot carry a baby. It is also unlikely to help after repeated failed cycles with poor-quality embryos or when pregnancy risks outweigh benefits; in these cases doctors discuss options such as donor eggs, a gestational carrier, or adoption. A reproductive-endocrinology team reviews ovarian reserve tests, overall health, and uterine anatomy to decide whether IVF, an alternative treatment, or avoiding pregnancy is the safest plan.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security